BUSINESS SEGMENT INFORMATION (Tables)

3 Months Ended

Mar. 31, 2023

Segment Reporting [Abstract]

Summary of Segment Reporting Information by Segment

The following table is a summary of segment information for the three months ended March 31, 2023 and 2022. Segment asset information is not presented since it is not used by the CODM at the operating segment level. Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income (loss) for the segment. General corporate activities included in the table below are comprised of general management and administrative corporate expenses, amortization and impairment of intangible assets and other operating income and expenses, net of certain general corporate activity costs that are allocated to the DIS and DS businesses. The accounting policies of the segments are the same as those of the Company as set forth in Note 2 to the audited consolidated financial statements contained in the Company’s 2022 Annual Report on Form 10-K and Note 2 to the interim unaudited consolidated financial statements.

	Three Months Ended March 31,
	2023		2022
Net revenues:
DIS business	$	2,259	$	2,541
All other operating segments	72		70
Total net revenues	$	2,331	$	2,611
Operating earnings (loss):
DIS business	$	374	$	562
All other operating segments	8		7
General corporate activities	(77)		(56)
Total operating income	305		513
Non-operating expense, net	(28)		(61)
Income before income taxes and equity in earnings of equity method investees	277		452
Income tax expense	(65)		(110)
Equity in earnings of equity method investees, net of taxes	5		31
Net income	217		373
Less: Net income attributable to noncontrolling interests	15		18
Net income attributable to Quest Diagnostics	$	202	$	355

Schedule of Revenues by Major Service

by major service for the three months ended March 31, 2023 and 2022 were as follows:

	Three Months Ended March 31,
	2023		2022
Routine clinical testing and other services	49	%	41	%
COVID-19 testing services	5		23
Gene-based and esoteric (including advanced diagnostics) testing services	37		28
Anatomic pathology testing services	6		5
All other	3		3
Net revenues	100	%	100	%